$RNTX News

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

Rein Therapeutics Begins Enrolling Patients In Phase 2 RENEW Trial

Maxim Group Initiates Coverage On Rein Therapeutics with Buy Rating, Announces Price Target of $4

Rein Therapeutics Inc. (RNTX) Shareholder/Analyst Call Prepared Remarks Transcript

All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Rein Therapeutics Q1 EPS $(0.19) Beats $(0.49) Estimate

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Rein Therapeutics shares are trading lower. The company issued an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis.

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Enrolled 8 Patients In RENEW Trial

Rein Therapeutics Files Prospectus For 30M Share Offering At ~$1.66/Share

Rein Therapeutics Q4 Adj. EPS $(0.11) Beats $(0.24) Estimate

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

Rein Therapeutics Doses First Patient In Phase 2 Trial Of LTI-03

Brookline Capital Downgrades Rein Therapeutics to Hold

Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Gets European Medicines Agency's Orphan Drug Designation For LTI-03